4D Pharma announced a major acquisition on Friday, gobbling up the production assets of Spanish-based contract research organisation Biomar. The AIM-traded pharmaceutical company, which focuses on the development of live biotherapeutics, said Biomar had been working as an outsourced development partner since 2014.
Plant Health Care reported on a year of growth on Friday, with both revenue and gross profit up as it continued to expand and develop its product range. The AIM-traded provider of patent-protected biological products to the agriculture sector saw revenue increase by 15% in constant currency and 9% in USD to $7.5m. It derived 60% of that revenue from proprietary sales of its Harpin and Myconate products.
Edenville En…
Read the full article at: http://www.digitallook.com/news/small-caps-news/small-caps-news-round-up–1111257.html